Virios Therapeutics, Inc. (NASDAQ:VIRI) Sees Large Increase in Short Interest

Virios Therapeutics, Inc. (NASDAQ:VIRI) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 570,300 shares, a growth of 70.1% from the May 31st total of 335,300 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is currently 0.5 days.

Analyst Ratings Changes

Separately, Maxim Group began coverage on Virios Therapeutics in a research note on Thursday, June 20th. They issued a “buy” rating and a $1.00 price target on the stock.

Virios Therapeutics Price Performance

Shares of NASDAQ VIRI traded down $0.02 during mid-day trading on Friday, hitting $0.22. The company had a trading volume of 938,482 shares, compared to its average volume of 2,136,266. The firm has a 50-day simple moving average of $0.30 and a two-hundred day simple moving average of $0.42. Virios Therapeutics has a one year low of $0.16 and a one year high of $2.42.

Virios Therapeutics (NASDAQ:VIRI) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. As a group, sell-side analysts predict that Virios Therapeutics will post -0.27 earnings per share for the current fiscal year.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.